WESTLEAF INC |
End-of-day quote
Other stock markets
|
||
| - CAD | - |
|
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Its low valuation, with P/E ratio at 3 and 1.71 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.61 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| 0.00% | 17.93M | - | ||
| +7.30% | 4.69B | B- | ||
| -31.08% | 3.66B | C+ | ||
| -0.71% | 3.11B | C | ||
| -24.32% | 2.65B | B- | ||
| -11.35% | 2.28B | - | D+ | |
| +34.19% | 1.78B | - | ||
| +33.49% | 1.37B | - | ||
| -15.07% | 1.39B | - | - | |
| +40.95% | 1.38B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- DB Stock
- WL Stock
- Ratings Westleaf Inc
